2024年ACC/AHA心力衰竭临床性能与质量测量指标更新
该文件是2020年ACC/AHA成人心力衰竭临床性能与质量测量指标的聚焦更新,新性能指标取自2022年AHA/ACC/HFSA心力衰竭管理指南中最强推荐(Class 1或Class 3)。新性能指标包括射血分数保留心衰患者的血压控制、射血分数降低心衰患者使用SGLT2抑制剂以及住院患者使用指南导向药物治疗。
要点
- 新性能指标聚焦HFpEF血压控制、HFrEF使用SGLT2抑制剂及住院GDMT。
- 新质量指标涵盖HFmrEF/HFpEF使用SGLT2抑制剂及干预前优化GDMT。
- 性能指标适用于公开报告或按绩效付费,质量指标暂不适用。
核心结论
- 新性能指标选自2022年心衰指南最强推荐(Class 1或Class 3),适用于公开报告或按绩效付费项目。
- 质量指标证据基础较弱,暂不适用于公开报告或按绩效付费,但可用于质量改进。
研究设计与样本
- 美国心脏协会/美国心脏病学会联合性能测量委员会制定的聚焦更新文件。
主要发现
- 新性能指标包括HFpEF患者最佳血压控制、HFrEF患者使用SGLT2抑制剂、住院患者使用GDMT。
- 新质量指标包括HFmrEF和HFpEF患者使用SGLT2抑制剂、慢性继发性重度二尖瓣反流干预前优化GDMT、射血分数改善心衰患者继续GDMT、识别心血管病已知风险和健康社会决定因素、心肌病患者避孕和妊娠风险以患者为中心的咨询、骨闪烁扫描评估转甲状腺素心脏淀粉样变性时需单克隆蛋白筛查排除轻链淀粉样变性。
临床怎么用
- 临床医生可依据新性能指标评估HFpEF血压控制、HFrEF的SGLT2抑制剂使用及住院GDMT。
- 质量指标可用于质量改进,但不宜用于公开报告或按绩效付费。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This document describes performance measures for heart failure that are appropriate for public reporting or pay-for-performance programs and is meant to serve as a focused update of the "2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures." The new performance measures are taken from the "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines" and are selected from the strongest recommendations (Class 1 or Class 3). In contrast, quality measures may not have as much evidence base and generally comprise metrics that might be useful for clinicians and health care organizations for quality improvement but are not yet appropriate for public reporting or pay-for-performance programs. New performance measures include optimal blood pressure control in patients with heart failure with preserved ejection fraction, the use of sodium-glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction, and the use of guideline-directed medical therapy in hospitalized patients. New quality measures include the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with mildly reduced and preserved ejection fraction, the optimization of guideline-directed medical therapy prior to intervention for chronic secondary severe mitral regurgitation, continuation of guideline-directed medical therapy for patients with heart failure with improved ejection fraction, identifying both known risks for cardiovascular disease and social determinants of health, patient-centered counseling regarding contraception and pregnancy risks for individuals with cardiomyopathy, and the need for a monoclonal protein screen to exclude light chain amyloidosis when interpreting a bone scintigraphy scan assessing for transthyretin cardiac amyloidosis.
引用
- Kittleson, Breathett, Ziaeian, et al. 2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures. J Am Coll Cardiol. 2024. PMID: 39127953. doi:10.1016/j.jacc.2024.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。